AstraZeneca rises after $2 billion equity investment in Summit Therapeutics
29/09/2026 08:11
BUZZ-AstraZeneca rises after $2 billion equity investment in Summit Therapeutics ** Shares of AstraZeneca AZN.L up 1.5% at £126.8
** Company makes a $2 billion equity investment in Summit Therapeutics through convertible preferred shares
** Investment is convertible into Summit common stock at $18.36 per share, representing an 18.6% premium to its last closing price
** Analysts at Jefferies said AZN's equity investment in SMMT and global clinical trial deal are strategically smart, giving its oncology ADC portfolio a clear route to PD-1xVEGF combinations
** As of last close, AZN down ~9.5% YTD
(Reporting by Atharva Singh in Bengaluru)
Recent news on Summit Therapeutics
See all newsBrief: Akeso Announces Summit Therapeutics And Ecog-Acrin Cancer Research Group Enter Into Phase Ii/Iii Clinical Trial Collaboration To Evaluate Ivonescimab In First-Line Biliary Tract Cancer
Factbox: Major drugmakers turn to China for licensing deals
Brief: Summit Therapeutics Announces Opening Of Global Phase Ii Study Of Ivonescimab-Based Regimens In Advanced Clear Cell Renal Cell Carcinoma
Factbox: Major drugmakers turn to China for licensing deals
AstraZeneca, Daiichi Sankyo partner with Summit to test cancer drug combination (updated)